Omeros Corp

Затворен

СекторЗдравеопазване

19.71 3.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.34

Максимум

19.14

Ключови измерители

By Trading Economics

Приходи

-38M

13M

Продажби

19M

29M

P/E

Средно за сектора

15.492

47.946

EPS

0.02

Марж на печалбата

46.381

Служители

175

EBITDA

-40M

18M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+46.67% upside

Дивиденти

By Acuity

Следващи печалби

12.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

385M

1.4B

Предишно отваряне

16.14

Предишно затваряне

19.71

Настроения в новините

By Acuity

21%

79%

39 / 340 Класиране в Healthcare

Omeros Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.10.2026 г., 20:07 ч. UTC

Omeros Corp shares are declining, reaching their lowest point mid-morning and finishing well below the 20-day moving average amid weaker overall market performance.

5.10.2026 г., 20:06 ч. UTC

Omeros Corp is advancing, reflecting a gain from Friday's close, despite pulling back from an earlier session high.

2.10.2026 г., 21:01 ч. UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend that has lasted for six consecutive sessions.

1.10.2026 г., 22:15 ч. UTC

Omeros Corp is trading modestly higher in after-market hours following five consecutive sessions of declines, despite mixed signals in the broader market.

30.09.2026 г., 19:46 ч. UTC

Omeros Corp shares fell modestly Wednesday, continuing a decline observed over the past three trading days, despite remaining above the 20-day moving average.

28.09.2026 г., 20:07 ч. UTC

Omeros Corp shares are declining, following a broader market trend, after peaking early in the session and reaching a low before the close.

24.09.2026 г., 19:35 ч. UTC

Omeros Corp shares fell sharply after an earlier gain, despite remaining above the 20-day moving average and near the upper end of its one-month range.

23.09.2026 г., 23:02 ч. UTC

Omeros Corp's stock declined in after-market trading, dropping from Wednesday's close despite remaining above its 20-day moving average.

22.09.2026 г., 20:02 ч. UTC

News
Social Media

Omeros shares advance sharply after Cantor Fitzgerald upgraded the stock to Overweight, citing strong Yartemlea launch and reinstating a $22 price target.

21.09.2026 г., 19:16 ч. UTC

Omeros Corp has advanced during Monday's trading session, reaching a notable peak earlier in the day while remaining below its 20-day moving average.

18.09.2026 г., 20:13 ч. UTC

Omeros Corp's shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

17.09.2026 г., 20:08 ч. UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16.09.2026 г., 19:36 ч. UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15.09.2026 г., 20:51 ч. UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14.09.2026 г., 23:06 ч. UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10.09.2026 г., 20:03 ч. UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

3.09.2026 г., 19:46 ч. UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2.09.2026 г., 23:01 ч. UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1.09.2026 г., 19:16 ч. UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31.08.2026 г., 23:16 ч. UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28.08.2026 г., 20:07 ч. UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27.08.2026 г., 22:01 ч. UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25.08.2026 г., 23:12 ч. UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21.08.2026 г., 19:16 ч. UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20.08.2026 г., 23:32 ч. UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19.08.2026 г., 22:51 ч. UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18.08.2026 г., 23:16 ч. UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15.08.2026 г., 00:01 ч. UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Ценова цел

By TipRanks

46.67% нагоре

12-месечна прогноза

Среден 27.5 USD  46.67%

Висок 33 USD

Нисък 22 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Omeros Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Настроение

By Acuity

39 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.